Description
AOD 9604 is a synthetic peptide derived from the C-terminal fragment (176–191) of human growth hormone (hGH), specifically developed to target fat metabolism pathways. Unlike full-length growth hormone, AOD 9604 has been studied for its ability to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat accumulation) without significant effects on blood glucose levels or insulin sensitivity.
Preclinical and early clinical research suggests that AOD 9604 acts on adipose tissue by promoting the mobilisation of stored fat and enhancing metabolic activity. Its mechanism is considered more selective compared to traditional growth hormone therapies, focusing primarily on fat metabolism rather than systemic growth effects.
AOD 9604 is commonly utilised in research settings investigating obesity, weight management, and metabolic optimisation, as well as in studies exploring targeted fat reduction pathways.
Key Clinical Benefits:
- Stimulates lipolysis (fat breakdown)
- Inhibits lipogenesis (fat accumulation)
- Targets adipose tissue metabolism
- Does not significantly impact glucose or insulin (in studies)
- Derived from hGH fragment (176–191)
